With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Rationale: Olaratumab is the PDGFRɑ-inhibitor marketed as the long awaited savior for soft-tissue sarcoma, and you’d think a wildly promising phase 2 trial would serve as reason enough to hope for a blockbuster hit with its phase 3 follow-on ANNOUNCE trial. Well, it wasn’t. Betting Line: Olaratumab doesn’t improve outcomes across a population with unselected unresectable soft-tissue sarcomas. | Tap, ASCO Plenary 2019